SCHEMBL3014870

SCHEMBL3014870

Cc1ccc(S(=O)(=O)N2CCN(c3nc(Cc4ccccc4C)cs3)CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.47
HTT P42858 2/20 0.47
ALDH1A1 P00352 2/20 0.47
PKM P14618 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TP53 P04637 1/20 0.47
TDP1 Q9NUW8 2/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
KDM4E B2RXH2 1/20 0.46
GBA1 P04062 6/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
LMNA P02545 2/20 0.44
MAPK1 P28482 2/20 0.44
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016682 0.93 NPSR1 (0.48) L3MBTL1HTTALDH1A1PKMSMN1; SMN2
SCHEMBL3017462 0.92 ALDH1A1 (0.58) L3MBTL1HTTALDH1A1PKMSMN1; SMN2
SCHEMBL3006628 0.92 HTT (0.47) HSD11B1L3MBTL1HTTALDH1A1PKM
SCHEMBL3019696 0.92 SMN1; SMN2 (0.46) L3MBTL1HTTALDH1A1SMN1; SMN2TDP1
SCHEMBL3012048 0.90 ALDH1A1 (0.44) HSD11B1L3MBTL1HTTALDH1A1SMN1; SMN2
SCHEMBL3010800 0.90 HSD11B1 (0.56) HSD11B1L3MBTL1ALDH1A1SMN1; SMN2TDP1
SCHEMBL3017637 0.90 SMN1; SMN2 (0.47) HSD11B1L3MBTL1HTTALDH1A1PKM
SCHEMBL2997804 0.89 GBA1 (0.45) HSD11B1L3MBTL1ALDH1A1SMN1; SMN2TDP1
SCHEMBL3001178 0.88 HSD11B1 (0.50) HSD11B1L3MBTL1HTTALDH1A1PKM
SCHEMBL3006243 0.88 MEN1 (0.52) HSD11B1L3MBTL1HTTALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA HSD11B1 1034/4885L3MBTL1 1847/4885HTT 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.